By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


InDex Pharmaceuticals AB 

Scheeles väg 2

Stockholm    SE-171 77  Sweden
Phone: 46-8-50884730 Fax: 46-8-50884739


Key Statistics

Ownership: Private

Web Site: InDex Pharmaceuticals AB


Company News
InDex Pharmaceuticals AB Receives Grant From Sweden's Innovation Agency Vinnova For Pre-Clinical Development Of DIMS Compounds In Inflammation 5/23/2016 12:45:12 PM
InDex Pharmaceuticals AB Receives FDA Clearance Of IND For Cobitolimod (Kappaproct) Phase IIb Trial 3/7/2016 10:08:22 AM
InDex Pharmaceuticals AB Receives Approval Of The International Nonproprietary Name (INN) Cobitolimod For Their Lead Drug Candidate Kappaproct 2/10/2016 9:19:43 AM
InDex Pharmaceuticals AB Appoints Uli Hacksell And Jesper Wiklund To Its Board Of Directors 7/9/2015 8:36:05 AM
InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis 6/30/2015 9:39:19 AM
Peter Zerhouni New CEO Of InDex Pharmaceuticals AB 2/5/2015 2:20:49 PM
InDex Pharmaceuticals AB To Present Results From The COLLECT Trial At The 10th Congress Of The European Crohn’s And Colitis Organization 2/3/2015 10:07:24 AM
InDex Pharmaceuticals AB Announces Results From COLLECT, A Clinical Trial Of Kappaproct® In The Treatment Of Moderate To Severe Ulcerative Colitis 6/27/2014 8:56:54 AM
InDex Pharmaceuticals AB Closes $20 Million Financing Round, Welcomes NeoMed As New Shareholder 2/25/2014 10:09:13 AM
InDex Pharmaceuticals AB Completes Patient Recruitment in P3 Ulcerative Colitis Study With Kappaproct 4/8/2013 11:35:35 AM